Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Clinical trial NCT06134193 · UNKNOWN

Trial details

NCT number: NCT06134193
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma Intrahepatic Cholangiocarcinoma Gallbladder Cancer Surufatinib Angiogenesis Inhibitors Tislelizumab Antineoplastic Agents, Immunological Immunotherapy

Start date: 2023-11-01
Primary completion: 2024-06-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.